Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer
A. Rydh et al., Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer, SC J UROL N, 33(2), 1999, pp. 89-93
Objective: In order to evaluate the negative predictive value of a low pros
tate-specific antigen (PSA) for a positive bone scan, we performed a retros
pective study in a patient material from the Umea region in Northern Sweden
. We also evaluated whether different tumour grades could influence this pr
edictive value. Material and Methods: Four-hundred-and-forty-six patients o
f newly diagnosed prostate cancer were reviewed. We analysed different leve
ls of PSA, tumour grade, tumour stage and combinations of these parameters
for their use in making a positive bone scintigraphy (BS) prediction. Resul
ts: Among 214 patients with PSA <20 ng/ml, 9 showed a positive BS. When tum
ours of grades 2 and 3 were excluded, the number of positive BS predictions
decreased to 6. For 350 of these 446 patients, a classification according
to TNM was available; 162 of these 350 had a PSA value <20 ng/ml, and when
this group comprised only small and well-differentiated tumours (T1-2, G1),
only one of the remaining 81 patients had a positive BS result. Conclusion
s: We conclude that in most patients with small and well-differentiated tum
ours (T1-2, G1) and PSA <20, BS staging need not be carried out.